Novo Nordisk's POSEIDON study of 18,904 patients across 18 countries found that 40% of people with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or heart failure have cardiovascular inflammation. This inflammation, measured by high-sensitivity C-reactive protein (hsCRP), is a key independent risk factor for heart attacks and strokes despite standard treatments controlling cholesterol, blood pressure, and blood sugar. The findings highlight a major gap in cardiovascular care and support the need for new therapies targeting inflammation to reduce residual cardiovascular risk. The study was presented at the 94th European Atherosclerosis Society Congress and underscores the importance of inflammation as a driver of cardiovascular disease progression and risk.
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
The European Medicines Agency's CHMP has recommended marketing authorization for Novo Nordisk's Wegovy 7.2 mg single-dose pen for obesity treatment in the EU. Clinical trials showed an average weight loss of 20.7% in obese patients, with about one-th...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
The European Medicines Agency's CHMP has recommended approval of Novo Nordisk's Wegovy pill (oral semaglutide) for weight management in the EU. The pill showed a mean weight loss of 16.6% in trials, comparable to the injectable version, and also redu...
